Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CADILA HEALTHCARE ALEMBIC PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 19.2 29.0 66.4% View Chart
P/BV x 7.4 4.7 159.0% View Chart
Dividend Yield % 0.5 0.7 69.4%  

Financials

 ALEMBIC PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
CADILA HEALTHCARE
Mar-20
ALEMBIC PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs664352 188.5%   
Low Rs412207 199.7%   
Sales per share (Unadj.) Rs208.7139.2 149.9%  
Earnings per share (Unadj.) Rs31.011.8 263.5%  
Cash flow per share (Unadj.) Rs37.118.6 199.9%  
Dividends per share (Unadj.) Rs5.503.50 157.1%  
Dividend yield (eoy) %1.01.3 81.6%  
Book value per share (Unadj.) Rs144.2101.4 142.3%  
Shares outstanding (eoy) m188.521,023.74 18.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.0 128.5%   
Avg P/E ratio x17.423.7 73.1%  
P/CF ratio (eoy) x14.515.0 96.4%  
Price / Book Value ratio x3.72.8 135.4%  
Dividend payout %17.729.8 59.6%   
Avg Mkt Cap Rs m101,461286,033 35.5%   
No. of employees `000NA13.4 0.0%   
Total wages/salary Rs m7,46724,145 30.9%   
Avg. sales/employee Rs ThNM10,632.7-  
Avg. wages/employee Rs ThNM1,801.2-  
Avg. net profit/employee Rs ThNM898.5-  
INCOME DATA
Net Sales Rs m39,347142,531 27.6%  
Other income Rs m941,139 8.2%   
Total revenues Rs m39,441143,670 27.5%   
Gross profit Rs m8,73624,198 36.1%  
Depreciation Rs m1,1526,965 16.5%   
Interest Rs m1843,418 5.4%   
Profit before tax Rs m7,49314,954 50.1%   
Minority Interest Rs m11288 3.8%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5683,198 49.0%   
Profit after tax Rs m5,84412,044 48.5%  
Gross profit margin %22.217.0 130.8%  
Effective tax rate %20.921.4 97.8%   
Net profit margin %14.98.5 175.8%  
BALANCE SHEET DATA
Current assets Rs m19,57787,154 22.5%   
Current liabilities Rs m14,89682,694 18.0%   
Net working cap to sales %11.93.1 380.2%  
Current ratio x1.31.1 124.7%  
Inventory Days Days9071 125.6%  
Debtors Days Days4594 48.3%  
Net fixed assets Rs m27,097133,236 20.3%   
Share capital Rs m3771,024 36.8%   
"Free" reserves Rs m26,811102,733 26.1%   
Net worth Rs m27,188103,757 26.2%   
Long term debt Rs m4,99332,146 15.5%   
Total assets Rs m47,778236,866 20.2%  
Interest coverage x41.75.4 775.8%   
Debt to equity ratio x0.20.3 59.3%  
Sales to assets ratio x0.80.6 136.9%   
Return on assets %12.66.5 193.3%  
Return on equity %21.511.6 185.2%  
Return on capital %23.613.7 171.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45352,752 36.9%   
Fx outflow Rs m6,06514,504 41.8%   
Net fx Rs m13,38838,248 35.0%   
CASH FLOW
From Operations Rs m8,12025,054 32.4%  
From Investments Rs m-7,556-10,123 74.6%  
From Financial Activity Rs m590-10,942 -5.4%  
Net Cashflow Rs m1,1533,989 28.9%  

Share Holding

Indian Promoters % 74.1 74.8 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 8.3 34.9%  
FIIs % 9.1 5.9 154.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 11.0 126.4%  
Shareholders   49,328 44,069 111.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 18, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS